137 related articles for article (PubMed ID: 24322028)
1. Effect of diet and omega-3 fatty acids in NAFLD.
Popescu LA; Vîrgolici B; Lixandru D; Miricescu D; Condruţ E; Timnea O; Ranetti AE; Militaru M; Mohora M; Zăgrean L
Rom J Morphol Embryol; 2013; 54(3 Suppl):785-90. PubMed ID: 24322028
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
Scorletti E; Byrne CD
Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease.
Alwayn IP; Gura K; Nosé V; Zausche B; Javid P; Garza J; Verbesey J; Voss S; Ollero M; Andersson C; Bistrian B; Folkman J; Puder M
Pediatr Res; 2005 Mar; 57(3):445-52. PubMed ID: 15659701
[TBL] [Abstract][Full Text] [Related]
4. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
6. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
Jump DB; Depner CM; Tripathy S; Lytle KA
Adv Nutr; 2015 Nov; 6(6):694-702. PubMed ID: 26567194
[TBL] [Abstract][Full Text] [Related]
7. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
[TBL] [Abstract][Full Text] [Related]
8. Role of diet and nutritional management in non-alcoholic fatty liver disease.
Fan JG; Cao HX
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
[TBL] [Abstract][Full Text] [Related]
9. Molecular interplay between Δ5/Δ6 desaturases and long-chain fatty acids in the pathogenesis of non-alcoholic steatohepatitis.
López-Vicario C; González-Périz A; Rius B; Morán-Salvador E; García-Alonso V; Lozano JJ; Bataller R; Cofán M; Kang JX; Arroyo V; Clària J; Titos E
Gut; 2014 Feb; 63(2):344-55. PubMed ID: 23492103
[TBL] [Abstract][Full Text] [Related]
10. Effect of maternal diet rich in omega-6 and omega-9 fatty acids on the liver of LDL receptor-deficient mouse offspring.
Torres Dde O; Dos Santos AC; Silva AK; Leite JI; De Souza JR; Beltrão EI; Peixoto CA
Birth Defects Res B Dev Reprod Toxicol; 2010 Apr; 89(2):164-70. PubMed ID: 20437476
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
[TBL] [Abstract][Full Text] [Related]
12. Fatty liver: role of inflammation and fatty acid nutrition.
Byrne CD
Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):265-71. PubMed ID: 20189787
[TBL] [Abstract][Full Text] [Related]
13. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Zaitone S; Hassan N; El-Orabi N; El-Awady el-S
Eur J Pharmacol; 2011 Jul; 662(1-3):70-7. PubMed ID: 21549113
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
[TBL] [Abstract][Full Text] [Related]
15. Effects of N-acetylcysteine on oxidative stress in rats with non-alcoholic steatohepatitis.
Samuhasaneeto S; Thong-Ngam D; Kulaputana O; Patumraj S; Klaikeaw N
J Med Assoc Thai; 2007 Apr; 90(4):788-97. PubMed ID: 17487136
[TBL] [Abstract][Full Text] [Related]
16. [Omega-3 fatty acids as an option in the treatment of NAFLD].
Singer P
MMW Fortschr Med; 2011 Oct; 153 Suppl 3():90-4. PubMed ID: 22184802
[TBL] [Abstract][Full Text] [Related]
17. Endogenously synthesized n-3 polyunsaturated fatty acids in fat-1 mice ameliorate high-fat diet-induced non-alcoholic fatty liver disease.
Kim EH; Bae JS; Hahm KB; Cha JY
Biochem Pharmacol; 2012 Nov; 84(10):1359-65. PubMed ID: 22981383
[TBL] [Abstract][Full Text] [Related]
18. Medium chain triglycerides dose-dependently prevent liver pathology in a rat model of non-alcoholic fatty liver disease.
Ronis MJ; Baumgardner JN; Sharma N; Vantrease J; Ferguson M; Tong Y; Wu X; Cleves MA; Badger TM
Exp Biol Med (Maywood); 2013 Feb; 238(2):151-62. PubMed ID: 23576797
[TBL] [Abstract][Full Text] [Related]
19. A lipidomic analysis of nonalcoholic fatty liver disease.
Puri P; Baillie RA; Wiest MM; Mirshahi F; Choudhury J; Cheung O; Sargeant C; Contos MJ; Sanyal AJ
Hepatology; 2007 Oct; 46(4):1081-90. PubMed ID: 17654743
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory effect of black soybean on hepatic cholesterol accumulation in high cholesterol and high fat diet-induced non-alcoholic fatty liver disease.
Jung JH; Kim HS
Food Chem Toxicol; 2013 Oct; 60():404-12. PubMed ID: 23900008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
